Ethical and scientific issues in studying the safety of approved drugs /

"An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on...

Full description

Saved in:
Bibliographic Details
Corporate Author: Institute of Medicine (U.S.). Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs.
Format: eBook
Language:English
Published: Washington, D.C. : National Academies Press, ©2012.
Series:Online access: National Academy of Sciences National Academies Press.
Online access: NCBI NCBI Bookshelf.
Subjects:
Online Access:CONNECT
CONNECT
LEADER 05531cam a2200661Ma 4500
001 mig00005391031
003 OCoLC
005 20210517045208.1
006 m o d
007 cr cn|||||||||
008 120529s2012 dcua ob 001 0 eng d
010 |z  2012021854 
019 |a 807995581  |a 813396136  |a 817819229  |a 961588569  |a 962602470  |a 988443543  |a 990687182  |a 992062784  |a 994403202  |a 1028757443  |a 1038657339  |a 1045517324  |a 1047272810  |a 1071917238  |a 1153543516  |a 1162391150  |a 1204377150  |a 1229716924 
020 |a 9780309218146  |q (electronic bk.) 
020 |a 0309218144  |q (electronic bk.) 
020 |z 9780309218139 
020 |z 0309218136 
020 |z 661394890X 
020 |z 9786613948908 
020 |z 1283636441 
020 |z 9781283636445 
035 |a (OCoLC)811594850  |z (OCoLC)807995581  |z (OCoLC)813396136  |z (OCoLC)817819229  |z (OCoLC)961588569  |z (OCoLC)962602470  |z (OCoLC)988443543  |z (OCoLC)990687182  |z (OCoLC)992062784  |z (OCoLC)994403202  |z (OCoLC)1028757443  |z (OCoLC)1038657339  |z (OCoLC)1045517324  |z (OCoLC)1047272810  |z (OCoLC)1071917238  |z (OCoLC)1153543516  |z (OCoLC)1162391150  |z (OCoLC)1204377150  |z (OCoLC)1229716924 
035 0 0 |a ocm00000001wrldshrocn811594850 
037 |a 3564274  |b Proquest Ebook Central 
040 |a CEF  |b eng  |e pn  |c CEF  |d CEF  |d INT  |d VT2  |d OCLCQ  |d OCLCO  |d AU@  |d ZCU  |d WYU  |d OCLCQ  |d OCLCO  |d UWO  |d LVT  |d YOU  |d OCLCQ  |d STF  |d AGLDB  |d DKC  |d OCLCO  |d OCLCQ  |d M8D  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCA  |d UKAHL  |d OCLCQ  |d OCLCA  |d UKCRE  |d VLY  |d AJS  |d OCLCO 
043 |a n-us--- 
049 |a TXMM 
050 4 |a RM301.27  |b .E84 2012 
060 4 |a QV 771 
082 0 4 |a 174.2/951  |2 23 
245 0 0 |a Ethical and scientific issues in studying the safety of approved drugs /  |c Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies. 
260 |a Washington, D.C. :  |b National Academies Press,  |c ©2012. 
300 |a 1 online resource (xvi, 275 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a data file  |2 rda 
500 |a Title screen viewed on Sept. 24, 2012. 
504 |a Includes bibliographical references and index. 
505 0 |a Introduction -- Incorporating benefit and risk assessment and benefit-risk management into food and drug administration decision-making -- Evidence and decision-making -- Selection and oversight of required postmarketing studies -- Synthesis -- Appendixes. 
520 |a "An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on the market. The discovery of new adverse events in the postmarketing setting is part of the normal natural history of approved drugs, and timely identification and warning about drug risks are central to the mission of the Food and Drug Administration (FDA). Not all risks associated with a drug are known at the time of approval, because safety data are collected from studies that involve a relatively small number of human subjects during a relatively short period. Written in response to a request by the FDA, Ethical and Scientific Issues in Studying the Safety of Approved Drugs discusses ethical and informed consent issues in conducting studies in the postmarketing setting. It evaluates the strengths and weaknesses of various approaches to generate evidence about safety questions, and makes recommendations for appropriate followup studies and randomized clinical trials. The book provides guidance to the FDA on how it should factor in different kinds of evidence in its regulatory decisions. Ethical and Scientific Issues in Studying the Safety of Approved Drugs will be of interest to the pharmaceutical industry, patient advocates, researchers, and consumer groups"--Publisher's description. 
546 |a English. 
590 |a EBSCO eBook Academic Comprehensive Collection North America 
650 0 |a Drugs  |x Testing  |x Moral and ethical aspects  |z United States. 
650 0 |a Drug approval  |z United States. 
650 0 |a Clinical trials  |x Moral and ethical aspects  |z United States. 
710 2 |a Institute of Medicine (U.S.).  |b Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs. 
730 0 |a WORLDSHARE SUB RECORDS 
776 0 8 |i Print version:  |t Ethical and scientific issues in studying the safety of approved drugs.  |d Washington, D.C. : National Academies Press, ©2012  |z 9780309218139  |w (DLC) 2012944110  |w (OCoLC)822995300 
830 0 |a Online access: National Academy of Sciences National Academies Press. 
830 0 |a Online access: NCBI NCBI Bookshelf. 
856 4 0 |u https://ezproxy.mtsu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=991052  |z CONNECT  |3 EBSCO  |t 0 
907 |a 4665072  |b 05-25-21  |c 07-02-20 
998 |a wi  |b 05-25-21  |c m  |d z   |e -  |f eng  |g dcu  |h 0  |i 2 
994 |a 92  |b TXM 
999 f f |i e4b86ad5-065a-4cc0-9193-7ae311c98812  |s e329eb26-94bf-4db5-a682-1906750272b6  |t 0 
952 f f |a Middle Tennessee State University  |b Main  |c James E. Walker Library  |d Electronic Resources  |t 0  |e RM301.27 .E84 2012  |h Library of Congress classification 
856 4 0 |3 EBSCO  |t 0  |u https://ezproxy.mtsu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=991052  |z CONNECT